RPS6KA1

Ribosomal protein S6 kinase alpha-1 · Q15418 · RPS6KA1 on Sugi Atlas →

26,982 patent compounds predicted against RPS6KA1, 20,163 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Gsk-690693 (SCHEMBL310452)	1.00	15/20
Hydrochloric Acid (SCHEMBL311235)	0.63	5/20
SCHEMBL311609	0.62	5/20
Hydrochloric Acid (SCHEMBL312002)	0.60	5/20
SCHEMBL310924	0.58	5/20
Uprosertib (SCHEMBL168584)	1.00	4/20
Hydrochloric Acid (SCHEMBL312213)	0.74	4/20
Hydrochloric Acid (SCHEMBL311202)	0.61	4/20
SCHEMBL159594	0.50	4/20
SCHEMBL311788	0.73	3/20
SCHEMBL157758	0.54	3/20
SCHEMBL311403	0.51	3/20
Ly-2584702 (SCHEMBL311653)	1.00	2/20
Ly-2584702 (SCHEMBL312564)	1.00	2/20
Tofacitinib (SCHEMBL322753)	1.00	2/20
Ly-2584702 (SCHEMBL311369)	0.98	2/20
SCHEMBL311654	0.67	2/20
SCHEMBL69095	0.60	2/20
SCHEMBL311708	0.59	2/20
SCHEMBL67376	0.58	2/20

Clinical trials — most relevant to RPS6KA1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder	PHASE2/PHASE3	RECRUITING
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Biased GRK Signaling Via β2-Adrenergic Receptors in Human Skeletal Muscle	PHASE2	NOT_YET_RECRUITING
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma	PHASE1/PHASE2	COMPLETED
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma	PHASE1/PHASE2	COMPLETED
Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery	PHASE2	COMPLETED
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis	PHASE1/PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)	PHASE1/PHASE2	COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
Therapeutic RSK1 Targeting in Myelofibrosis	PHASE1	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment	PHASE1	COMPLETED
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	PHASE1	WITHDRAWN
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Testing of Micellar Casein, Blended Micellar Casein and Native Whey	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory	nan	COMPLETED
The Effects of Whey vs. Collagen on MPS	nan	COMPLETED
ADAR1 Expression Level in Rectal Cancer	nan	RECRUITING
NK Cell Deregulation in HBV Patients	nan	ACTIVE_NOT_RECRUITING
Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RPS6KA1 binder may also engage these)

Protein	Name	Similarity
Q6PFQ0	—	1.000	Q6PFQ0 →
Q63531	—	1.000	Q63531 →
P10665	—	1.000	P10665 →
P18652	—	1.000	P18652 →
P18654	—	1.000	P18654 →
RPS6KA3	Ribosomal protein S6 kinase alpha-3	1.000	landscape →
RPS6KA2	Ribosomal protein S6 kinase alpha-2	1.000	landscape →
P18653	—	1.000	P18653 →
P10666	—	1.000	P10666 →
Q7TPS0	—	1.000	Q7TPS0 →
Q9WUT3	—	0.999	Q9WUT3 →
Q5R4K3	—	0.999	Q5R4K3 →
RPS6KA6	Ribosomal protein S6 kinase alpha-6	0.997	landscape →
RPS6KA5	Ribosomal protein S6 kinase alpha-5	0.997	landscape →
Q5F3L1	—	0.996	Q5F3L1 →
Q21734	—	0.996	Q21734 →
Q8C050	—	0.996	Q8C050 →
Q6U1I9	—	0.995	Q6U1I9 →
Q6NW76	—	0.994	Q6NW76 →
PNCK	Calcium/calmodulin-dependent protein kinase type 1B	0.993	landscape →
Q18846	—	0.993	Q18846 →
A8XJQ6	—	0.993	A8XJQ6 →
P11730	—	0.992	P11730 →
Q9NBK5	—	0.992	Q9NBK5 →
Q9FMP5	—	0.992	Q9FMP5 →
Q9WVC6	—	0.992	Q9WVC6 →
Q755C4	—	0.991	Q755C4 →
Q6DEH3	—	0.991	Q6DEH3 →
Q384J7	—	0.991	Q384J7 →
STK32A	Serine/threonine-protein kinase 32A	0.991	landscape →